|drug3720||Standard care delivered in the isolation hospitals. Wiki||1.00|
There is one clinical trial.
African American adults, specifically those managing chronic disease and social isolation, are one of the most vulnerable groups susceptible to COVID-19. This intervention involves a multi-disciplinary and culturally sensitive approach to address two major COVID-19 related challenges in this population. First, this program collaborates with predominantly African American churches to implement Federal and State guidelines aimed at preventing outbreaks of COVID-19 at faith-based gatherings. Second, this program trains church-based health advisors to help African American older parishioners manage their chronic health conditions and reduce psychological distress during the pandemic.
Description: From pre-intervention to three-month post-intervention, a 30% change is anticipated for chronic physical and mental disease management among African American older adultsMeasure: Percentage of Participants Achieving Improvement of Health Conditions Using the Severity of Medical Chronic Conditions Surveys Time: 3 months
Description: From pre-intervention to three-month post-intervention, an 80% change is anticipated in knowledge, attitude, and behaviors of COVID-19 risk among African American older adultsMeasure: Percentage of Participants Achieving Target Levels of Knowledge, Attitude, and Behaviors with NIH Toolbox Surveys Time: 3 months
Description: From pre-intervention to three-month post-intervention, a 40% change is anticipated for COVID-19 testing among the population of African American Older adults.Measure: Prevalence of COVID-19 testing using Participant COVID-19 Test History Survey Time: 3 months
Description: From pre-intervention to three-month post-intervention, a 70% change is anticipated in uptake of pneumococcal and influenza vaccinations among the population of African American Older adults.Measure: Prevalence of pneumococcal and influenza vaccinations using Participant Immunization History Survey Time: 3 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports